Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43


Artificial Intelligence in Drug Treatment.

Romm EL, Tsigelny IF.

Annu Rev Pharmacol Toxicol. 2019 Jul 26. doi: 10.1146/annurev-pharmtox-010919-023746. [Epub ahead of print]


ANKRD9 is a metabolically-controlled regulator of IMPDH2 abundance and macro-assembly.

Hayward D, Kouznetsova VL, Pierson HE, Hasan NM, Guzman ER, Tsigelny IF, Lutsenko S.

J Biol Chem. 2019 Jul 23. pii: jbc.RA119.008231. doi: 10.1074/jbc.RA119.008231. [Epub ahead of print]


Recognition of early and late stages of bladder cancer using metabolites and machine learning.

Kouznetsova VL, Kim E, Romm EL, Zhu A, Tsigelny IF.

Metabolomics. 2019 Jun 20;15(7):94. doi: 10.1007/s11306-019-1555-9.


Polycomb repressive 2 complex-Molecular mechanisms of function.

Kouznetsova VL, Tchekanov A, Li X, Yan X, Tsigelny IF.

Protein Sci. 2019 Aug;28(8):1387-1399. doi: 10.1002/pro.3647. Epub 2019 Jun 10. Review.


APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy.

Boichard A, Pham TV, Yeerna H, Goodman A, Tamayo P, Lippman S, Frampton GM, Tsigelny IF, Kurzrock R.

Oncoimmunology. 2018 Dec 24;8(3):1550341. doi: 10.1080/2162402X.2018.1550341. eCollection 2019.


In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma.

Bush KT, Boichard A, Tsigelny IF.

Anticancer Res. 2018 Apr;38(4):1967-1977.


Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma.

Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasaz A, Lanman RB, Lippman S, Kurzrock R.

Oncologist. 2018 May;23(5):586-593. doi: 10.1634/theoncologist.2017-0479. Epub 2018 Feb 27.


Artificial intelligence in drug combination therapy.

Tsigelny IF.

Brief Bioinform. 2018 Feb 9. doi: 10.1093/bib/bby004. [Epub ahead of print]


Cripto stabilizes GRP78 on the cell membrane.

Kouznetsova VL, Hu H, Teigen K, Zanetti M, Tsigelny IF.

Protein Sci. 2018 Mar;27(3):653-661. doi: 10.1002/pro.3358. Epub 2017 Dec 27.


Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.

Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S.

Cancer Discov. 2018 Feb;8(2):164-173. doi: 10.1158/2159-8290.CD-17-1009. Epub 2017 Dec 1.


BRAF mutation as a novel driver of eosinophilic cystitis.

Choi MY, Tsigelny IF, Boichard A, Skjevik ÅA, Shabaik A, Kurzrock R.

Cancer Biol Ther. 2017 Sep 2;18(9):655-659. doi: 10.1080/15384047.2017.1360449. Epub 2017 Aug 22.


High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations.

Boichard A, Tsigelny IF, Kurzrock R.

Oncoimmunology. 2017 Jan 31;6(3):e1284719. doi: 10.1080/2162402X.2017.1284719. eCollection 2017.


A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.

Wrasidlo W, Tsigelny IF, Price DL, Dutta G, Rockenstein E, Schwarz TC, Ledolter K, Bonhaus D, Paulino A, Eleuteri S, Skjevik ÅA, Kouznetsova VL, Spencer B, Desplats P, Gonzalez-Ruelas T, Trejo-Morales M, Overk CR, Winter S, Zhu C, Chesselet MF, Meier D, Moessler H, Konrat R, Masliah E.

Brain. 2016 Dec;139(Pt 12):3217-3236. Epub 2016 Sep 27.


Molecular mechanisms of OLIG2 transcription factor in brain cancer.

Tsigelny IF, Kouznetsova VL, Lian N, Kesari S.

Oncotarget. 2016 Aug 16;7(33):53074-53101. doi: 10.18632/oncotarget.10628.


Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma.

Tsigelny IF, Mukthavaram R, Kouznetsova VL, Chao Y, Babic I, Nurmemmedov E, Pastorino S, Jiang P, Calligaris D, Agar N, Scadeng M, Pingle SC, Wrasidlo W, Makale MT, Kesari S.

Oncotarget. 2017 Apr 4;8(14):22370-22384. doi: 10.18632/oncotarget.5633.


The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2).

Tsai CY, Liebig JK, Tsigelny IF, Howell SB.

Metallomics. 2015 Nov;7(11):1477-87. doi: 10.1039/c5mt00131e. Epub 2015 Jul 24.


Cisplatin inhibits MEK1/2.

Yamamoto T, Tsigelny IF, Götz AW, Howell SB.

Oncotarget. 2015 Sep 15;6(27):23510-22.


Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer.

Tsigelny IF, Wheler JJ, Greenberg JP, Kouznetsova VL, Stewart DJ, Bazhenova L, Kurzrock R.

Oncotarget. 2015 Mar 20;6(8):6029-39.


Hierarchical control of coherent gene clusters defines the molecular mechanisms of glioblastoma.

Tsigelny IF, Kouznetsova VL, Jiang P, Pingle SC, Kesari S.

Mol Biosyst. 2015 Apr;11(4):1012-28. doi: 10.1039/c5mb00007f.


Molecular determinants of α-synuclein mutants' oligomerization and membrane interactions.

Tsigelny IF, Sharikov Y, Kouznetsova VL, Greenberg JP, Wrasidlo W, Overk C, Gonzalez T, Trejo M, Spencer B, Kosberg K, Masliah E.

ACS Chem Neurosci. 2015 Mar 18;6(3):403-16. doi: 10.1021/cn500332w. Epub 2015 Jan 21.


Discovery of substituted 4-aminoquinazolines as selective Toll-like receptor 4 ligands.

Nour A, Hayashi T, Chan M, Yao S, Tawatao RI, Crain B, Tsigelny IF, Kouznetsova VL, Ahmadiiveli A, Messer K, Pu M, Corr M, Carson DA, Cottam HB.

Bioorg Med Chem Lett. 2014 Nov 1;24(21):4931-8. doi: 10.1016/j.bmcl.2014.09.039. Epub 2014 Sep 22.


Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.

Wrasidlo W, Crews LA, Tsigelny IF, Stocking E, Kouznetsova VL, Price D, Paulino A, Gonzales T, Overk CR, Patrick C, Rockenstein E, Masliah E.

Br J Pharmacol. 2014 Dec;171(24):5757-73. doi: 10.1111/bph.12875.


bHLH Transcription factors inhibitors for cancer therapy: general features for in silico drug design.

Tsigelny IF, Kouznetsova VL, Pingle SC, Kesari S.

Curr Med Chem. 2014;21(28):3227-43. Review.


Structural diversity of Alzheimer's disease amyloid-β dimers and their role in oligomerization and fibril formation.

Tsigelny IF, Sharikov Y, Kouznetsova VL, Greenberg JP, Wrasidlo W, Gonzalez T, Desplats P, Michael SE, Trejo-Morales M, Overk CR, Masliah E.

J Alzheimers Dis. 2014;39(3):583-600. doi: 10.3233/JAD-131589.


Development of a pharmacophore model for the catecholamine release-inhibitory peptide catestatin: virtual screening and functional testing identify novel small molecule therapeutics of hypertension.

Tsigelny IF, Kouznetsova VL, Biswas N, Mahata SK, O'Connor DT.

Bioorg Med Chem. 2013 Sep 15;21(18):5855-69. doi: 10.1016/j.bmc.2013.07.008. Epub 2013 Jul 17.


p75 neurotrophin receptor is a clock gene that regulates oscillatory components of circadian and metabolic networks.

Baeza-Raja B, Eckel-Mahan K, Zhang L, Vagena E, Tsigelny IF, Sassone-Corsi P, Ptácek LJ, Akassoglou K.

J Neurosci. 2013 Jun 19;33(25):10221-34. doi: 10.1523/JNEUROSCI.2757-12.2013.


Identification of substituted pyrimido[5,4-b]indoles as selective Toll-like receptor 4 ligands.

Chan M, Hayashi T, Mathewson RD, Nour A, Hayashi Y, Yao S, Tawatao RI, Crain B, Tsigelny IF, Kouznetsova VL, Messer K, Pu M, Corr M, Carson DA, Cottam HB.

J Med Chem. 2013 Jun 13;56(11):4206-23. doi: 10.1021/jm301694x. Epub 2013 May 24.


Direct recognition of superparamagnetic nanocrystals by macrophage scavenger receptor SR-AI.

Chao Y, Karmali PP, Mukthavaram R, Kesari S, Kouznetsova VL, Tsigelny IF, Simberg D.

ACS Nano. 2013 May 28;7(5):4289-98. doi: 10.1021/nn400769e. Epub 2013 Apr 30.


A hierarchical coherent-gene-group model for brain development.

Tsigelny IF, Kouznetsova VL, Baitaluk M, Changeux JP.

Genes Brain Behav. 2013 Mar;12(2):147-65. doi: 10.1111/gbb.12005. Epub 2012 Dec 28.


An all-atom model of the structure of human copper transporter 1.

Tsigelny IF, Sharikov Y, Greenberg JP, Miller MA, Kouznetsova VL, Larson CA, Howell SB.

Cell Biochem Biophys. 2012 Jul;63(3):223-34. doi: 10.1007/s12013-012-9358-x.


Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation.

Tsigelny IF, Sharikov Y, Wrasidlo W, Gonzalez T, Desplats PA, Crews L, Spencer B, Masliah E.

FEBS J. 2012 Mar;279(6):1000-13. doi: 10.1111/j.1742-4658.2012.08489.x. Epub 2012 Feb 27.


Elucidation of common pharmacophores from analysis of targeted metabolites transported by the multispecific drug transporter-Organic anion transporter1 (Oat1).

Kouznetsova VL, Tsigelny IF, Nagle MA, Nigam SK.

Bioorg Med Chem. 2011 Jun 1;19(11):3320-40. doi: 10.1016/j.bmc.2011.04.045. Epub 2011 Apr 28.


Conformational changes of the multispecific transporter organic anion transporter 1 (OAT1/SLC22A6) suggests a molecular mechanism for initial stages of drug and metabolite transport.

Tsigelny IF, Kovalskyy D, Kouznetsova VL, Balinskyi O, Sharikov Y, Bhatnagar V, Nigam SK.

Cell Biochem Biophys. 2011 Nov;61(2):251-9. doi: 10.1007/s12013-011-9191-7.


Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1).

Wikoff WR, Nagle MA, Kouznetsova VL, Tsigelny IF, Nigam SK.

J Proteome Res. 2011 Jun 3;10(6):2842-51. doi: 10.1021/pr200093w. Epub 2011 Apr 22.


Tetramerization domain mutations in KCNA5 affect channel kinetics and cause abnormal trafficking patterns.

Burg ED, Platoshyn O, Tsigelny IF, Lozano-Ruiz B, Rana BK, Yuan JX.

Am J Physiol Cell Physiol. 2010 Mar;298(3):C496-509. doi: 10.1152/ajpcell.00464.2009. Epub 2009 Dec 16.


Analysis of metagene portraits reveals distinct transitions during kidney organogenesis.

Tsigelny IF, Kouznetsova VL, Sweeney DE, Wu W, Bush KT, Nigam SK.

Sci Signal. 2008 Dec 9;1(49):ra16. doi: 10.1126/scisignal.1163630.


Modeling of glycerol-3-phosphate transporter suggests a potential 'tilt' mechanism involved in its function.

Tsigelny IF, Greenberg J, Kouznetsova V, Nigam SK.

J Bioinform Comput Biol. 2008 Oct;6(5):885-904.


Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.

Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E.

PLoS One. 2008 Sep 4;3(9):e3135. doi: 10.1371/journal.pone.0003135.


Mechanism of alpha-synuclein oligomerization and membrane interaction: theoretical approach to unstructured proteins studies.

Tsigelny IF, Sharikov Y, Miller MA, Masliah E.

Nanomedicine. 2008 Dec;4(4):350-7. doi: 10.1016/j.nano.2008.05.005. Epub 2008 Jul 18.


MAPAS: a tool for predicting membrane-contacting protein surfaces.

Sharikov Y, Walker RC, Greenberg J, Kouznetsova V, Nigam SK, Miller MA, Masliah E, Tsigelny IF.

Nat Methods. 2008 Feb;5(2):119. doi: 10.1038/nmeth0208-119. No abstract available.


Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein.

Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, Miller MA, Keller SH, Platoshyn O, Yuan JX, Masliah E.

FEBS J. 2007 Apr;274(7):1862-77.


Complex dynamics of chaperone-protein interactions under cellular stress.

Tsigelny IF, Nigam SK.

Cell Biochem Biophys. 2004;40(3):263-76.


Supplemental Content

Loading ...
Support Center